Apollo Hospitals Q2 Net Profit Jumps 32% to ₹630 Cr; Bed Occupancy Reaches 73%
Apollo Hospitals delivered a 32% YoY rise in Q2 FY27 consolidated net profit to ₹630 crore on revenue of ₹7,615 crore, with hospital occupancy improving to 73%.

Key Takeaways
- Consolidated revenue from operations expanded 23.0% year-on-year to ₹7,615 crore for the second quarter ended September 30, 2026.
- Consolidated profit after tax grew 32.0% YoY to ₹630 crore, supported by a 29% increase in operating EBITDA to ₹1,191 crore.
- Healthcare Services (Hospitals) occupancy improved to 73%, while digital platform Apollo HealthCo reached operational breakeven.
Apollo Hospitals Enterprise Limited, India's premier integrated healthcare delivery conglomerate, reported a 32.0% year-on-year expansion in consolidated net profit to ₹630 crore for the second quarter ended September 30, 2026. Consolidated revenue from operations climbed 23.0% YoY to ₹7,615 crore from ₹6,189 crore in Q2 FY26, driven by higher hospital bed occupancy, rising inpatient surgical volumes, and profitability inflection at its digital pharmacy arm.
What Happened
The healthcare major delivered consolidated operating EBITDA of ₹1,191 crore, up 29.0% YoY, maintaining robust enterprise operating margins of 15.64%. The primary Healthcare Services (hospital operations) vertical generated revenue of ₹3,900 crore (+23% YoY) with an EBITDA of ₹937 crore, driven by a 14% increase in inpatient surgical procedures across oncology, cardiology, gastroenterology, and robotic organ transplants. Total operational hospital bed occupancy improved to 73% during the quarter compared to 69% in Q2 FY26, while average revenue per patient (ARPP) advanced 8% YoY to ₹1,86,880.
Q2 FY27 Healthcare & Segment Financial Snapshot
| Segment / Operational Metric | Q2 FY27 | Q2 FY26 | YoY Change (%) |
|---|---|---|---|
| Consolidated Revenue from Operations | ₹7,615 Cr | ₹6,189 Cr | +23.0% |
| Consolidated Operating EBITDA | ₹1,191 Cr | ₹923 Cr | +29.0% |
| Operating EBITDA Margin (%) | 15.64% | 14.91% | +73 bps |
| Consolidated Net Profit (PAT) | ₹630 Cr | ₹477 Cr | +32.0% |
| Healthcare Services (Hospitals) Revenue | ₹3,900 Cr | ₹3,171 Cr | +23.0% |
| Apollo HealthCo (Pharmacy & Digital) Revenue | ₹3,286 Cr | ₹2,672 Cr | +23.0% |
| Hospital Bed Occupancy Ratio (%) | 73.00% | 69.00% | +400 bps |
| Average Revenue Per Patient (ARPP) (₹) | ₹1,86,880 | ₹1,73,040 | +8.0% |
| International Medical Tourism Revenue | ₹425 Cr | ₹310 Cr | +37.1% |
Apollo HealthCo, the omni-channel pharmacy distribution and Apollo 24/7 digital healthcare vertical, expanded revenue 23% to ₹3,286 crore and achieved operational breakeven at the EBITDA level, eliminating a drag on consolidated earnings.
Sector Context & Earnings Quality
Demand for tertiary and quaternary healthcare in India is experiencing structural expansion, driven by rising non-communicable disease prevalence, expanding penetration of private health insurance, and India's growing status as a medical tourism destination. International medical tourism revenues surged 37.1% YoY to ₹425 crore, supported by patient inflows from Bangladesh, the Middle East, Central Asia, and East Africa for complex surgical treatments. In addition, diagnostic clinics network AHLL recorded 20% revenue expansion to ₹429 crore.
Independent TradeKaizen Analysis & Key Risks
TradeKaizen Analysis: Apollo Hospitals is executing a highly profitable transition into an integrated healthcare ecosystem. Achieving operational breakeven at Apollo HealthCo represents a pivotal turning point for the stock: the market previously discounted Apollo's valuation due to persistent quarterly cash burn in digital customer acquisition. With digital healthcare operating costs self-funded, the hospital division's strong 24% return on capital employed (ROCE) and 73% occupancy flow directly into consolidated net profit growth. Planned bed additions of 2,500 beds over the next three years provide clear capacity expansion runways.
Key risks include clinical attrition among specialized surgical specialists, regulatory capping on medical device implant pricing by government authorities, and execution delays in commissioning planned greenfield hospital facilities in Gurugram and Chennai.
Disclaimer: This report is for informational purposes only and does not constitute investment advice.
Sources & References
- View sourceNSE Corporate FilingsExchange / Regulatory Filing
Unaudited Consolidated Financial Results for the Second Quarter Ended September 30, 2026
- View sourceBusiness StandardNews Report
Apollo Hospitals Q2 Net Profit Rises 32% to ₹630 Crore; HealthCo Achieves Breakeven
TradeKaizen Markets Desk
Equities & Market Coverage Desk
The TradeKaizen Markets Desk covers Indian equities, index movements, institutional flows, and exchange disclosures from NSE and BSE.
